Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK.

Diabetes Care. 2009 Jul;32(7):1218-20. doi: 10.2337/dc09-0053. Epub 2009 Apr 14.

2.

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T.

Metabolism. 2006 Sep;55(9):1227-31.

PMID:
16919543
3.

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7. Epub 2005 Feb 24.

4.

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ.

Diabetologia. 2006 Nov;49(11):2756-62. Epub 2006 Sep 13.

PMID:
16969649
5.

Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA.

Am J Cardiol. 2007 Feb 15;99(4):513-8. Epub 2006 Dec 28.

PMID:
17293196
6.

Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.

Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL.

Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):129-34. doi: 10.1016/j.numecd.2008.03.004. Epub 2008 Jul 2.

PMID:
18595673
7.

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.

Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

Diabetes Metab Res Rev. 2008 Feb;24(2):109-14.

PMID:
17694504
8.

Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.

Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ.

Coron Artery Dis. 2009 Jun;20(4):267-73. doi: 10.1097/MCA.0b013e32832c459c.

PMID:
19440065
9.

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

Microvasc Res. 2008 May;76(1):52-6. doi: 10.1016/j.mvr.2007.09.004. Epub 2007 Oct 5.

PMID:
18474381
10.

Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden.

Basta G, Del Turco S, Navarra T, Mazzarisi A, Cocci F, Coceani M, Bianchi M, Schlueter M, Marraccini P.

J Atheroscler Thromb. 2012;19(10):941-8. Epub 2012 Jul 6.

11.

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D.

Arch Neurol. 2005 Nov;62(11):1734-6.

PMID:
16286548
12.

High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.

Basta G, Castagnini M, Del Turco S, Epistolato MC, Righini P, Sangiorgi GM, De Caterina R, Tanganelli P.

Eur J Clin Invest. 2009 Dec;39(12):1065-72. doi: 10.1111/j.1365-2362.2009.02212.x. Epub 2009 Oct 7.

PMID:
19811526
13.

Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.

Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T.

Diabetes Metab Res Rev. 2007 Jul;23(5):368-71.

PMID:
17024691
14.

The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.

Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E.

Clin Biochem. 2008 Aug;41(12):981-5. doi: 10.1016/j.clinbiochem.2008.05.007. Epub 2008 May 27.

PMID:
18538667
15.

Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study.

de Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA, Peshock R, Libby P.

Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2192-6. Epub 2005 Aug 18.

16.

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

Geroldi D, Falcone C, Emanuele E.

Curr Med Chem. 2006;13(17):1971-8. Review.

PMID:
16842191
17.

Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.

Nakamura K, Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi S.

Metabolism. 2009 Mar;58(3):421-5. doi: 10.1016/j.metabol.2008.10.020.

PMID:
19217461
18.
19.

Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA).

Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, Szklo M, Greenland P, Blumenthal RS.

Circulation. 2007 Aug 7;116(6):619-26. Epub 2007 Jul 23.

20.

Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension.

Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R.

J Hypertens. 2005 Sep;23(9):1725-9.

PMID:
16093918

Supplemental Content

Support Center